ASX Announcement

10 February 2022

TGA Registration Update (3)

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") provides an update on its Therapeutic Goods Administration (TGA) submission for the registration of its EuGeni Reader and SARS CoV-2 Ag Rapid Diagnostic Test (RDT).

In response to TGA's review of the submission, AnteoTech intends to collect further clinical data based on samples collected directly from patients and immediately analysed on the EuGeni Reader (prospective samples). Australian and European clinical research organisations are coordinating these clinical trials.

AnteoTech has had ongoing and constructive discussions with the TGA over the past week. These discussions focused on the reconciliation of AnteoTech's clinical data set, which includes stored and direct patient samples, and the TGA's requirements for additional clinical evidence. Following these discussions, it has been concluded that AnteoTech's proposed approach of conducting new clinical trials represents the most expeditious pathway to meeting these data requirements.

The data generated from these trials will ensure that a new submission by AnteoTech will meet the TGA's regulatory requirements, as well as providing the Company with data for additional regulatory approval processes, including registration for the EU Common List. The trials will also provide further evidence of performance relating to new variants of concern listed by the World Health Organisation ("WHO"), lower limit of detection and other performance measures from a vaccinated population.

By undertaking a new submission, AnteoTech has the flexibility and opportunity to compile the new clinical data from studies in Australia and Europe and present this as a fresh and unencumbered submission to the TGA.

AnteoTech will provide updates as key milestones are achieved.

CEO Derek Thomson said: *"We have worked directly with the TGA to understand the most efficient method of supplying the data they now require and our highest priority is to generate this data as quickly as possible. These further trials will provide AnteoTech with the opportunity to gain additional clinical data which will enhance the growing body of evidence for performance of both the EuGeni Reader and the RDT."*

AnteoTech Ltd
ACN 070 028 625
Unit 4, 26 Brandl Street, Eight Mile Plains, QLD, 4113
Australia

T +61 7 3219 0085
E investors@anteotech.com
anteotech.com

AnteoTech is also pleased to announce that Pierre Nathie has joined the company as of January on a full-time basis as Head of Life Science Products and Services. Pierre brings 25 years' experience in executing and implementing international IVD launch strategies and has delivered multiple IVD products to market and managed go-to-market cycles, from initial product concept up to "ready-to-launch" stage.

ENDS

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538

About AnteoTech - (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on Twitter (@AnteoTech_), LinkedIn.

Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive **Latest News** bulletin, our email alert service.